Q-omics provides the consensus-scored PSMD6 profile across patient tissues and cancer cell-line models. PSMD6 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PSMD6 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, PSMD6 protein abundance shows 21,327 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, LIHC, and GBM as cancer lineages where PSMD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMD6 survival associations across molecular data types. PSMD6 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMD6 RNA expression–survival associations across cancer types. High PSMD6 expression shows unfavorable associations in KICH, LIHC, ACC, LGG and KIRC, but favorable associations in BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for PSMD6 RNA expression.
This table summarizes PSMD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PSMD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMD6 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, COAD, BRCA and STAD. The LIHC box plot shows higher PSMD6 RNA expression in tumor versus normal tissue (log2 FC = +0.706, t-test p < 0.001).
This table shows molecular features associated with PSMD6 in patient tissues and cancer cell lines. In patient samples, PSMD6 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
